CD27 and B-cell non-Hodgkin lymphoma: There is also an extensive literature concerning abnormalities of B cell repopulation after rituximab (anti-CD20) treatment, including a delayed recovery of circulating CD27+ memory B cells and/or changes in immunoglobulin repertoires, in patients with autoimmune diseases (RA, systemic lupus erythematosus, and active primary Sjögren’s syndrome) or with B cell non-Hodgkin lymphoma (B cell NHL) (25–31, 33).